A recent study using European adverse-event reports reveals complex patterns of suicidality linked to antidepressant use, with demographic variations and an emphasis on vigilant monitoring during early treatment.
A new analysis of European adverse-event reports has reopened an old and uneasy question in psychiatry: whether antidepressants can, in some patients, coincide with suicidal thoughts or behaviour. The Psychology Today article says the study, published in Pharmaceuticals, examined reports submitted to EudraVigilance between 2001 and 2024 for six widely prescribed drugs, but it also stresses an important limitation: pharmacovigilance data can show signals, not prove that a medicine caused an outcome.
What the researchers found was not a simple drug-by-drug ranking, but a pattern that varied by outcome. Psychiatric reactions accounted for roughly a third of all reports across the six medicines. Venlafaxine produced the largest absolute number of psychiatric reports, while duloxetine had the highest share relative to its total reports. When completed suicide, attempts, ideation and related categories were separated, the picture became more complicated still, with venlafaxine leading in completed suicides and citalopram and fluoxetine showing the highest proportions relative to their overall report totals.
The study also found clear demographic skews. Women accounted for more reported adverse events than men across every drug, with the widest gaps seen for duloxetine and sertraline. The authors suggest several possible explanations, including biological differences, but also the likelihood that reporting behaviour differs by sex. Age patterns were equally striking: adults aged 18 to 64 generated the highest number of suicide-attempt reports overall, while the 0 to 17 group showed a different distribution, with sertraline, fluoxetine and escitalopram accounting for a sizeable share of attempts.
That age profile fits with older clinical evidence showing that antidepressant-related suicidality is strongly age-dependent. A BMJ meta-analysis of randomised trials found that the increased risk in people under 25 approached that seen in children and adolescents, while the net effect in adults aged 25 to 64 was broadly neutral for suicidal behaviour and possibly protective for suicidal ideation. In older adults, the same analysis suggested antidepressants may reduce both suicidality and suicidal behaviour. A separate 27-year observational study likewise found antidepressant treatment was associated with a lower risk of suicidal behaviour, although it still urged close monitoring when treatment begins.
The practical message from the new report is therefore less about alarm than vigilance. The article argues that the first weeks after starting treatment remain the period of greatest concern, when energy may improve before mood does. It also points out that under-reporting in pharmacovigilance systems means official figures may capture only a small fraction of real-world events. For clinicians and patients alike, the safest course remains careful follow-up, especially for children, adolescents and older adults, and prompt reporting of any mood change, agitation or suicidal thought.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
